NEW YORK, April 4, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol Myers” or the “Company”) (NYSE: BMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Bristol Myers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 13, 2024, the U.S. Food and Drug Administration (“FDA”) posted briefing documents in advance of meeting of the Oncologic Drugs Advisory Committee, scheduled for March 15, 2024, regarding Bristol Myers’s CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted by Bristol Myers.
On this news, Bristol Myers’s stock price fell $1.75 per share, or 3.22%, to close at $52.65 per share on March 13, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP